Literature DB >> 19129183

The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5.

Effi Wies1, Alexander S Hahn, Katharina Schmidt, Cornelia Viebahn, Nadine Rohland, Anja Lux, Tim Schellhorn, Angela Holzer, Jae U Jung, Frank Neipel.   

Abstract

Kaposi's sarcoma-associated herpesvirus encodes four genes with homology to the family of interferon regulatory factors (IRFs). At least one of these viral IRFs, vIRF-3, is expressed in latently Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma (PEL) cells and is essential for the survival of PEL cells. We now report that vIRF-3 interacts with cellular IRF-5, thereby inhibiting binding of IRF-5 to interferon-responsive promoter elements. Consequently, vIRF-3 blocked IRF-5-mediated promoter activation. A central double helix motif present in vIRF-3 was sufficient to abrogate both DNA binding and transcriptional transactivation by IRF-5. Upon DNA damage or activation of the interferon or Toll-like receptor pathways, cytoplasmic IRF-5 has been reported to be translocated to the nucleus, which results in induction of both p53-independent apoptosis and p21-mediated cell cycle arrest. We report here that IRF-5 is present in the nuclei of PEL cells without interferon stimulation. Silencing of vIRF-3 expression in PEL cells was accompanied by increased sensitivity to interferon-mediated apoptosis and up-regulation of IRF-5 target genes. In addition, vIRF-3 antagonized IRF-5-mediated activation of the p21 promoter. The data presented here indicate that vIRF-3 contributes to immune evasion and sustained proliferation of PEL cells by releasing IRF-5 from transcription complexes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129183      PMCID: PMC2659211          DOI: 10.1074/jbc.M809252200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation.

Authors:  L Zhang; J S Pagano
Journal:  Semin Cancer Biol       Date:  2001-12       Impact factor: 15.707

2.  Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes.

Authors:  B J Barnes; P A Moore; P M Pitha
Journal:  J Biol Chem       Date:  2001-04-12       Impact factor: 5.157

3.  Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53.

Authors:  Toshiki Mori; Yoshio Anazawa; Megumi Iiizumi; Seisuke Fukuda; Yusuke Nakamura; Hirofumi Arakawa
Journal:  Oncogene       Date:  2002-04-25       Impact factor: 9.867

Review 4.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Stephen K Tyring; Martin Stuschke; Michael Roggendorf; Robert A Schwartz; Siegfried Seeber
Journal:  Lancet Infect Dis       Date:  2002-06       Impact factor: 25.071

5.  Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes.

Authors:  Betsy J Barnes; Merrill J Kellum; Ann E Field; Paula M Pitha
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

6.  The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation.

Authors:  M Esteban; M A García; E Domingo-Gil; J Arroyo; C Nombela; C Rivas
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

7.  Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors.

Authors:  Charles Cunningham; Suzanne Barnard; David J Blackbourn; Andrew J Davison
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

8.  A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia.

Authors:  Rainer Wessely; Ludger Hengst; Birgit Jaschke; Franziska Wegener; Thomas Richter; Raffaella Lupetti; Makarios Paschalidis; Albert Schömig; Richard Brandl; Franz-Josef Neumann
Journal:  Hum Mol Genet       Date:  2003-01-15       Impact factor: 6.150

Review 9.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Stephen K Tyring; Martin Stuschke; Michael Roggendorf; Robert A Schwartz; Siegfried Seeber
Journal:  Lancet Infect Dis       Date:  2002-05       Impact factor: 25.071

Review 10.  Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?

Authors:  Patrick S Moore; Yuan Chang
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

View more
  38 in total

Review 1.  Immune evasion by Kaposi's sarcoma-associated herpesvirus.

Authors:  Hye-Ra Lee; Stacy Lee; Preet M Chaudhary; Parkash Gill; Jae U Jung
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  Critical role of IRF-5 in regulation of B-cell differentiation.

Authors:  Chunyang Lien; Chee-Mun Fang; David Huso; Ferenc Livak; Runqing Lu; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

Review 3.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

Review 4.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

Review 5.  Recognition of herpesviruses by the innate immune system.

Authors:  Søren R Paludan; Andrew G Bowie; Kristy A Horan; Katherine A Fitzgerald
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

6.  A Rhesus Rhadinovirus Viral Interferon (IFN) Regulatory Factor Is Virion Associated and Inhibits the Early IFN Antiviral Response.

Authors:  Gabriela Morin; Bridget A Robinson; Kelsey S Rogers; Scott W Wong
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 7.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

Review 8.  Diverse mechanisms evolved by DNA viruses to inhibit early host defenses.

Authors:  Marni S Crow; Krystal K Lum; Xinlei Sheng; Bokai Song; Ileana M Cristea
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-09-21       Impact factor: 8.250

9.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.

Authors:  Katharina Schmidt; Effi Wies; Frank Neipel
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.

Authors:  Jianmin Zuo; Andrew D Hislop; Carol S Leung; Shereen Sabbah; Martin Rowe
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.